Topical tranexamic acid VS topical adrenaline in reduction of intraoperative blood loss in FESS

Effect of addition of topical tranexamic acid to standard topical adrenaline in reduction of intraoperative blood loss in functional endoscopic sinus surgery: A Randomized controlled trial. - NIL

Status

Active, not recruiting

Phases

Phase 1Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/12/098946

Enrollment

Registered

2025-12-11

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J329- Chronic sinusitis, unspecified

Interventions

Intervention1: Adrenaline: standard topical adrenaline Control Intervention1: tranexamic acid: Addition of intraoperative topical tranexamic acid to standard topical adrenaline

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients aged 18 to 65 years undergoing FESS for chronic rhinosinusitis, defined by EPOS 2020 criteria who have undergone optimun medical medical treatment

Exclusion criteria

Exclusion criteria: patients aged less than 18years and more than 65 years

Design outcomes

Primary

Measure	Time frame
To determine the effect of adding intraoperative topical tranexamic acid to standard topical adrenaline on intraoperative blood loss during functional endoscopic sinus surgery (FESS).Timepoint: Intraoperatively	—

Secondary

Measure	Time frame
1. To compare the surgical field visibility between the two groups using Boezzart scaling 2. To compare the need for additional hemostatic measures during surgery in both groups 3. To compare the number of repeat applications of the solutions in each group Timepoint: 2.5-3 hours (duration of surgery)	—

Countries

India

Contacts

Public ContactChethana

Bharati Hospital and Research Centre, Pune

chethanahande@gmail.com9067275961

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026